A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs KAR 5585 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; First in man
  • Sponsors Karos Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 29 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 26 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top